Palbociclib plus fulvestrant clinical outcomes PALOMA-3

In the PALOMA-3 trial, palbociclib plus fulvestrant improved progression-free survival by approximately 5 months, overall survival by 6.9 months, and doubled time to chemotherapy in patients with hormone receptor-positive, HER2-negative metastatic breast cancer progressing on prior endocrine therapy, with a manageable safety profile dominated by reversible hematologic toxicity.

Abstract

The PALOMA-3 trial demonstrated substantial clinical benefit for palbociclib plus fulvestrant in hormone receptor-positive, HER2-negative metastatic breast cancer that progressed on prior endocrine therapy. Across multiple analyses with follow-up extending to 73.3 months, palbociclib plus fulvestrant consistently improved median progression-free survival by approximately 5 months compared to placebo plus fulvestrant (9.2-11.2 months vs 3.8-4.6 months, HR 0.42-0.50, p<0.001). The most recent analysis showed median overall survival of 34.8 months versus 28.0 months (HR 0.81, 95% CI 0.65-0.99), with greater benefit observed in patients with endocrine-sensitive disease who had not received prior chemotherapy for metastatic disease (39.3 vs 29.7 months, HR 0.72). Palbociclib plus fulvestrant doubled the median time to receipt of chemotherapy (17.6 vs 8.8 months, HR 0.58, p<0.001).

The safety profile was characterized by predictable hematologic toxicity, with grade 3-4 neutropenia occurring in 52-65% of patients but febrile neutropenia remaining low at 0.6-4.1%. Treatment discontinuation rates due to adverse events were minimal (2.0-2.6%), and dose intensity was maintained at 89.7% despite frequent dose modifications. Clinical benefit was consistent across menopausal status, geographic populations including Asian patients (HR 0.485), and molecular subtypes, with palbociclib providing benefit regardless of ESR1, PIK3CA, or TP53 mutation status. Quality of life was maintained with no significant deterioration from baseline.

Methods

We analyzed 10 sources from an initial pool of 200, using 8 screening criteria. Each paper was reviewed for 8 key aspects that mattered most to the research question.

Screening

We screened in sources based on their abstracts that met these criteria:

• Patient Population - Disease Type: Does this study involve patients with hormone receptor-positive, HER2-negative advanced or metastatic breast cancer who have experienced disease progression on prior endocrine therapy?
• Intervention Type: Does this study evaluate palbociclib in combination with fulvestrant as the primary intervention?
• Clinical Outcomes Reported: Does this study report clinical outcomes including efficacy endpoints (progression-free survival, overall survival, objective response rate) and/or safety outcomes?
• Study Design: Is this study a randomized controlled trial, systematic review, meta-analysis, or post-hoc analysis of the PALOMA-3 trial?
• Patient Age: Does this study involve adult patients (≥18 years)?
• Combination Therapy Focus: Does this study focus on the combination of palbociclib plus fulvestrant (rather than focusing solely on palbociclib monotherapy or fulvestrant monotherapy)?
• Human Clinical Evidence: Is this a human clinical study (not a preclinical study, in vitro study, animal study, case report, or case series)?
• Full Publication Available: Is this a full-text publication (not a conference abstract without full-text publication available)?

Data extraction

Efficacy Outcomes

• Primary endpoint results: Median PFS, hazard ratio, 95% CI, p-value
• Time to key outcomes: Time to chemotherapy, Time to next treatment

Safety Profile

• Adverse events: Most common adverse events (any grade and grade 3-4) with percentages for each treatment arm

Patient Characteristics

• Sample size per treatment arm
• Disease characteristics (HR/HER2 status, visceral disease percentage, ECOG performance status)

Follow-up Duration

• Median follow-up duration

Treatment Details

• Palbociclib dosing: 125 mg daily for 3 weeks followed by 1 week off over 28-day cycles.
• Fulvestrant dosing: 500 mg intramuscularly on days 1 and 15 of cycle 1, then on day 1 of subsequent 28-day cycles.

Results

Characteristics of Included Studies

The review included 10 publications reporting results from the PALOMA-3 trial, a randomized, double-blind, phase 3 study evaluating palbociclib plus fulvestrant versus placebo plus fulvestrant in patients with hormone receptor-positive, HER2-negative metastatic breast cancer that progressed on prior endocrine therapy. The PALOMA-3 trial randomized 521 women with hormone receptor-positive, HER2-negative metastatic breast cancer in a 2:1 ratio to receive palbociclib plus fulvestrant (n=347) or placebo plus fulvestrant (n=174). The median age was 57 and 56 years, with 79% of patients being post-menopausal. At baseline, 60% had visceral disease, 79% were sensitive to prior endocrine therapy, and 33% had received prior chemotherapy for advanced disease.

Progression-Free Survival

The primary endpoint of progression-free survival (PFS) showed consistent and substantial improvement with palbociclib plus fulvestrant across multiple analyses. Interim analyses reported median PFS of 9.2 months for palbociclib plus fulvestrant versus 3.8 months for placebo plus fulvestrant (HR 0.42, 95% CI 0.32-0.56, p<0.001). The most recent long-term analysis reported median PFS of 11.2 months versus 4.6 months (HR 0.50, 95% CI 0.40-0.62, one-sided p<0.0001).

Overall Survival

Overall survival (OS) analyses evolved with longer follow-up. The initial prespecified OS analysis with 44.8 months of follow-up showed median OS of 34.9 months for palbociclib plus fulvestrant versus 28.0 months for placebo plus fulvestrant (HR 0.81, 95% CI 0.64-1.03, p=0.09), representing a 6.9-month absolute difference.

Safety and Tolerability

The safety profile of palbociclib plus fulvestrant was characterized predominantly by asymptomatic hematologic toxicity. The overall rate of any grade adverse events was 98% for palbociclib plus fulvestrant versus 89% for placebo plus fulvestrant, with grade 3-4 events occurring in 70% versus 18% of patients, respectively.

Subgroup Analyses

Subgroup analyses demonstrated consistent benefit of palbociclib plus fulvestrant across pre-specified stratification factors, with meaningful trends in various subgroups including endocrine sensitivity.

Biomarker Analyses

Circulating tumor DNA (ctDNA) analysis was performed using a targeted panel of 17 genes in 331 patients at day 1. Low circulating tumor fraction (<10%) was associated with longer PFS, serving as a favorable prognostic factor.

Patient-Reported Outcomes

Patient-reported outcomes were assessed as a secondary endpoint, maintaining quality of life with no statistically significant changes from baseline observed.

Synthesis

The PALOMA-3 trial demonstrated consistent and clinically meaningful benefit of adding palbociclib to fulvestrant in hormone receptor-positive, HER2-negative metastatic breast cancer across multiple analyses spanning over 6 years of follow-up.